Effective anti-BCMA retreatment in multiple myeloma

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• Anti-B-cell maturation antigen (BCMA) therapies, including CAR T-cells, bispecific antibodies, and antibody-drug conjugates, represent a significant advancement in multiple myeloma (MM) treatment.
• Despite their promise, a cure for MM remains elusive, necessitating exploration of sequential therapeutic strategies.

Purpose of the Study:

• To report two cases of serial anti-BCMA therapy administration in multiple myeloma.
• To monitor BCMA expression and anti-CAR antibodies during sequential treatment.
• To discuss resistance mechanisms and inform future treatment strategies.

Main Methods:

• Case series reporting serial anti-BCMA therapy.
• Parallel monitoring of BCMA expression.
• Assessment of anti-CAR antibodies.
• Review of clinical data on anti-BCMA therapy resistance.

Main Results:

• Presented two cases of sequential anti-BCMA therapy.
• Observed changes in BCMA expression and anti-CAR antibodies during treatment.
• Identified key resistance mechanisms including antigen escape, BCMA shedding, anti-drug antibodies, T-cell exhaustion, and immunosuppressive microenvironment.

Conclusions:

• Sequential anti-BCMA therapies are a viable strategy for managing multiple myeloma.
• Understanding resistance mechanisms is crucial for optimizing serial treatment protocols.
• Further research is needed to refine sequential anti-BCMA therapy approaches for improved patient outcomes.